

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A ~~pharmaceutical preparation~~ composition, which comprises a) an activator for plasma coagulation factor and b) an amount, sufficient for promoting coagulation, of natural or synthetic RNA, ~~or of one or more coagulation-promoting fragments of natural or synthetic RNA, RNA analogs, or peptide-nucleic acids, ribozymes or RNA aptamers.~~
2. (Canceled) ~~The pharmaceutical preparation as claimed in claim 1, which further comprises an activator for a plasma coagulation factor.~~
3. (Currently Amended) The composition of claim 1, wherein the activator for plasma coagulation factor is selected from factor VII activating protease, the proenzyme of factor VII activating protease, factor XII, kinogen, and prekallikrein.
4. (Withdrawn) A method for promoting coagulation, comprising administering the pharmaceutical preparation as claimed in claim 1 or 3 to a patient.
5. (Withdrawn) A pharmaceutical preparation, which comprises an amount, sufficient for promoting fibrinolysis or inhibiting coagulation, of one or more RNA-degrading or -inhibiting compounds with ribonucleolytic activity or RNA-complexing capacity.

6. (Withdrawn) The pharmaceutical preparation as claimed in claim 5, which further comprises an activator for a plasma fibrinolytic.

7. (Withdrawn) The pharmaceutical preparation as claimed in claim 6, which comprises factor VII-activating protease or its proenzyme as activator for a plasma fibrinolytic.

8. (Withdrawn) A diagnostic aid for detecting postoperative hypercoagulable states, complications of pregnancy, tumor status, acute myocardial infarction or sepsis, wherein said diagnostic aid is used in the detection of an increased plasma RNA content compared with healthy people.

9. (Withdrawn) A diagnostic aid for quantitative or qualitative detection of coagulation factor VII-activating protease or of its proenzyme, which comprises a sufficient amount of natural or synthetic RNA, of active fragments of natural or synthetic RNA or RNA analogs, peptide nucleic acids, ribozymes or RNA aptamers for determination

- a) of the inactivating effect on coagulation factors VIII/VIIIa or V/Va or
- b) of the shortening effect on coagulation times in global coagulation tests or
- c) of the activating effect on plasminogen activators or
- d) of the activating effect on FVII.

10. (Withdrawn) A diagnostic aid as claimed in claim 8, which comprises a

sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers for determination of the effect shortening the coagulation time by means

- a) of the non-activated partial thromboplastin time (NAPTT) or
- b) of the prothrombin time (PT) or
- c) of the plasma recalcification time or
- d) of the activated partial thromboplastin time (APTT).

11. (Withdrawn) A diagnostic aid as claimed in claim 8 or 9, which comprises a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers for determination of the effect activating or enhancing the plasminogen activators through the activation

- a) of single-chain urokinase (scuPA, single-chain urokinase plasminogen activator) or
- b) of single-chain tPA (sctPA, single-chain tissue plasminogen activator).

12. (Withdrawn) A pharmaceutical preparation as claimed in claim 5, which comprises an amount, sufficient for the treatment of sepsis, of one or more RNA-degrading, inhibiting or complexing compounds.

13. (New) The composition of claim 3, wherein the activator for plasma coagulation factor is selected from factor VII activating protease and the proenzyme of factor VII activating protease.